Loading...
01/11 16:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals solid financial performance with revenue growth, improved gross profit, and increased adjusted EPS. Despite a slight decline in net income, the overall financial health is strong, with no debt and substantial cash reserves. The Q&A section highlights optimism in new product adoption and international expansion, although some answers lacked clarity. Given the market cap of $2.7 billion, these factors suggest a moderate positive impact on the stock price, likely resulting in a 2% to 8% increase over the next two weeks.
Revenue $298.4 million for Q4 2024, grew 11% year-over-year; $1.17 billion for full year 2024, grew 7% year-over-year, primarily due to an increase in the number of clients and covered lives.
Medical Revenue $188 million for Q4 2024, increased 9.4% year-over-year; $730 million for full year 2024, grew 7.9% year-over-year, driven by the same factors impacting overall revenue growth.
Pharmacy Revenue $111 million for Q4 2024, increased 13% year-over-year; $438 million for full year 2024, grew 6% year-over-year, attributed to the same factors affecting overall revenue.
Gross Profit $63.4 million for Q4 2024, increased 11% year-over-year, yielding a gross margin of 21.3%, a slight improvement from the previous year; $253 million for full year 2024, increased 6% year-over-year, with a gross margin of 21.7%, a slight decrease from the prior year.
Adjusted EBITDA $47.5 million for Q4 2024, increased 10% year-over-year, yielding a margin of 15.9%; $198.8 million for full year 2024, increased 6% year-over-year, with a margin of 17%, comparable to the prior year.
Net Income $10.5 million or $0.11 per diluted share for Q4 2024, compared to $13.5 million or $0.13 per share in the year-ago period; $54.3 million or $0.57 per diluted share for full year 2024, compared to $62 million or $0.62 per share in 2023, primarily due to a higher provision for income taxes.
Adjusted EPS $0.42 for Q4 2024, compared to $0.32 in the year-ago period; $1.64 for full year 2024, compared to $1.40 in 2023.
Operating Cash Flow $52.2 million for Q4 2024, compared to $37.7 million in the year-ago period; $179 million for full year 2024, below $189 million from the year-ago period, impacted by a previously disclosed amended agreement with pharmacy partners.
Days Sales Outstanding (DSO) Improved by 10 days from 2023, reflecting ongoing discipline in revenue cycle management.
Total Working Capital Approximately $304 million as of December 31, including $228 million of cash, cash equivalents, and marketable securities, with no debt.
New Services Launched: Progyny launched new services in maternity, postpartum, and menopause, with 20% of existing clients and 40% of new clients adopting these programs.
Acquisition of Benefit Bump: Progyny acquired Benefit Bump to enhance navigation of family-friendly benefits for employees, improving member experience and ROI for clients.
New Client Acquisition: Progyny added 80 new clients and 1.1 million new covered lives in Q4 2024, including Cigna as their first national health plan partner.
Market Positioning: Progyny is positioned as the preferred choice in women's health for sophisticated organizations, with a strong pipeline for new client engagement.
Client Retention Rate: Progyny achieved a client retention rate of 99%.
Operational Efficiencies: G&A expenses improved slightly to 10.4% of revenue due to efficiencies in back-office operations.
Product Roadmap: Progyny has a multiyear product roadmap to expand its platform and address gaps in women's and family health.
Investment in Digital Solutions: Progyny plans to invest in digital solutions and integrate recent acquisitions to enhance member experience.
Competitive Pressures: Progyny faces competitive pressures as it aims to maintain its market position in women's health solutions, particularly with the entry of new players and existing competitors enhancing their offerings.
Regulatory Issues: The company must navigate regulatory challenges that could impact its operations and compliance, particularly in the healthcare sector.
Supply Chain Challenges: There are potential supply chain challenges that could affect the delivery of services and products, particularly in the context of healthcare services.
Economic Factors: Economic factors, including inflation and changes in healthcare spending, may impact client budgets and the overall demand for Progyny's services.
Client Retention: While Progyny reported a high client retention rate of 99%, the loss of a large client for 2025 poses a risk to revenue and growth projections.
Utilization Variability: There is a risk of variability in member engagement and utilization rates, which could affect revenue projections and operational performance.
Integration of Acquisitions: The integration of recent acquisitions may present challenges that could impact operational efficiency and the realization of expected synergies.
New Covered Lives: Progyny added 1.1 million new covered lives and over 80 new logos in Q4 2024.
Client Retention: The company retained 99% of its clients.
Product Development: Progyny launched new services in maternity, postpartum, and menopause.
Acquisition Strategy: The company is integrating recent acquisitions to enhance its service offerings.
Sales Strategy: Progyny aims to add at least 1 million new lives in every selling season.
Market Positioning: Progyny is positioned as the preferred choice for women's health among sophisticated organizations.
Revenue Guidance Q1 2025: Projected revenue between $300 million to $318 million, reflecting growth of 8% to 14%.
Revenue Guidance Full Year 2025: Projected revenue of $1.175 billion to $1.225 billion, reflecting growth of 1% to 5%.
Adjusted EBITDA Q1 2025: Expected adjusted EBITDA between $53 million to $57 million.
Net Income Q1 2025: Projected net income between $15 million to $17.8 million.
Adjusted EBITDA Full Year 2025: Expected adjusted EBITDA between $188 million to $201 million.
Net Income Full Year 2025: Projected net income between $45 million to $53.9 million.
Share Repurchase Program: None
The earnings call shows a positive sentiment with strong financial health, no debt, and expanding profit margins. The Q&A section reveals management's confidence despite minor headwinds, with no significant risks identified. Guidance is stable, and there is potential for upselling new products. The market cap suggests moderate volatility, aligning with a positive stock price reaction.
The earnings call highlights strong financial performance with increased gross margins, net income, and record ART cycles. Despite slightly lower EBITDA margins, revenue growth in fertility and pharmacy segments is robust. The Q&A reveals positive engagement, pipeline recovery, and no adverse impact from industry layoffs. Guidance remains optimistic, and demand for services is rising across company sizes. The market cap suggests moderate volatility, aligning with a positive stock price movement expectation of 2% to 8% in the short term.
The earnings report shows strong financial performance with a 16.5% revenue increase, improved gross margins, and a record high in ART cycles. Despite some uncertainties in utilization rates and macroeconomic factors, the company maintained a robust client base and expanded its offerings. The Q&A session reflected management's confidence in growth, with no slowdowns in RFP activities. Although there were some unclear responses, the overall positive financial metrics and optimistic guidance suggest a positive stock price movement, especially given the company's small-cap status.
The earnings call reveals solid financial performance with revenue growth, improved gross profit, and increased adjusted EPS. Despite a slight decline in net income, the overall financial health is strong, with no debt and substantial cash reserves. The Q&A section highlights optimism in new product adoption and international expansion, although some answers lacked clarity. Given the market cap of $2.7 billion, these factors suggest a moderate positive impact on the stock price, likely resulting in a 2% to 8% increase over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
